Popular filter options for allergy trials
Peanut Allergy Clinical Trials
View 20 Peanut Allergy medical studies.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Food Allergy Clinical Trials
View 20 Food Allergy medical studies.
Immunotherapy
Multi OIT +1 More for Food Allergy
The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.
Herbal Medicine
FAHF-2 (TM) for Food Allergy
The increasing prevalence of allergic diseases in westernized countries poses a significant health problem and a tremendous burden on quality of life and healthcare expenditure. Food allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and shellfish are often life-long. Currently, there are no treatments that can cure or provide long-term remission from food allergy. Based on our preliminary studies, we hypothesize that our investigational botanical drug, FAHF-2TM, will be a safe and effective herbal therapy for food allergy. We are enrolling those age 12-45 yrs old with allergies to peanut, tree nuts, sesame, fish, and/or shellfish.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Phase 3 Allergy Clinical Trials
View 97 phase 3 allergy medical studies.
Hormone Therapy
Androgen Ablation Therapy + Chemotherapy for Prostate Cancer
This trial is studying androgen-ablation therapy and docetaxel to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Allergy Clinical Trials With No Placebo
View 97 allergy medical studies that do not have a placebo group.
Skin testing and Graded Oral Challenge for Penicillin Allergy
False diagnosis of penicillin allergy are frequently reported, and have been proven detrimental to patients. Current guidelines for the assessment of drug allergies recommend that penicillin allergy be evaluated first with prick and intradermal skin tests, and then completed with a graded oral challenge, spread over at least two doses. However, it has been shown that these skin tests, in addition to consuming resources and time, are of limited, or even doubtful validity, given the poor predictive values that have been reported in the modern penicillins era. It now seems unreasonable to continue their use without addressing other, more efficient diagnostic stategies. Several groups have now demonstrated the safety, validity, and efficiency of a direct, two-step amoxicillin oral challenge (starting with 10% of the standard therapeutic dose, followed by 90 % of the dose), without prior skin tests, first for any type of reaction in the pediatric population, then for any non-immediate reaction in the adult population. The objective of this study is to demonstrate the safety, efficiency, and validity of direct, two-step graded oral challenge with amoxicillin for the evaluation of any reported penicillin allergy in the adult population, excluding high-risk patients (documented anaphylaxis to a penicillin in the last 5 years). Skin tests will first be performed according to the protocol currently in use at the CHUL, then consented patients will proceed with the graded oral challenge still according to the protocol currently in use at the CHUL, but regardless of the skin tests results. The results of the two tests will be compared to determine the safety, efficiency and validity of proceeding directly to the graded oral challenge.
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is designed to compare the effectiveness of proactive and reactive treatment methods for atopic dermatitis (AD) in infants. The proactive treatment includes the use of a skin barrier cream or moisturizer and the proactive use of fluticasone propionate cream. The reactive treatment for AD is currently the standard of care and does not include the proactive use of these two products. The aim is to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
View More Allergy Trials
See another 64 medical studies focused on allergy.
Frequently Asked Questions
Introduction to allergy
What are the top hospitals conducting allergy research?
When it comes to cutting-edge clinical trials addressing allergies, several hospitals are at the forefront of innovation. Massachusetts General Hospital in Boston is currently conducting four active allergy trials and made history by recording their first trial in this field just last year, in 2021. In New york City, the Icahn School of Medicine at Mount Sinai is also actively engaged with four ongoing allergy trials. Although they have yet to record any completed trials specifically for allergies, their expertise and dedication make them a vital player in the field.
Meanwhile, Western Sky Medical Research located in El Paso has three active allergy trials underway and an impressive track record of ten previously conducted investigations since their inaugural allergy trial debuted back in 2007. On the other hand, Novartis Investigative Sites both in Louisville and Baltimore may not have any recorded past or completed allergy trials but are currently contributing with two active studies each.
These top hospitals represent beacons of hope for individuals dealing with allergies across the country. With research efforts focused on understanding allergic reactions better and developing new treatments, these institutions play a crucial role in improving lives affected by this widespread condition. By pushing boundaries through innovative clinical trials, they aim to bring relief and advancements that will enhance our overall quality of life amidst allergen-filled environments that challenge us daily
Which are the best cities for allergy clinical trials?
Chicago, Illinois; Boston, Massachusetts; and New york, New York emerge as the top cities for allergy clinical trials. In Chicago, there are 20 ongoing trials investigating treatments like iREACH CDS Tool, Prebiotic, and Tri-lipid skin barrier cream (Epiceram). Boston follows closely with 8 active trials focusing on Peanut SLIT-tablet, Ligelizumab 120 mg, and Segmental allergen challenge. Meanwhile, New York hosts 7 studies examining DBV1605 and Ligelizumab 120 mg among others. These cities provide individuals with allergies access to cutting-edge research and potential breakthroughs in treatment options.
Which are the top treatments for allergy being explored in clinical trials?
Allergy research is a field of ongoing exploration, with several promising treatments currently being studied in clinical trials. Leading the pack are sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), both showing potential to revolutionize allergy treatment. SLIT involves placing allergen extracts under the tongue to desensitize the immune system, while OIT focuses on gradually increasing exposure to allergens through controlled ingestion. These innovative approaches offer hope for improved management and long-term relief for individuals suffering from allergies.
What are the most recent clinical trials for allergy?
Exciting advancements in allergy research have led to the emergence of several recent clinical trials. Ligelizumab, a medication being evaluated in Phase 3 trials at a dose of 120 mg, shows promise as a potential treatment for allergies. Another trial focuses on remibrutinib, which is undergoing Phase 2 testing at low doses with encouraging results. Additionally, researchers are exploring the effectiveness of oral challenges and peanut SLIT-tablets to better understand and manage allergies. In another study, investigators are evaluating Abrocitinib at a dosage of 100mg for its potential impact on allergic reactions. These clinical trials offer hope for improved treatments that can enhance the quality of life for individuals affected by allergies.
What allergy clinical trials were recently completed?
A noteworthy clinical trial has recently concluded, shedding light on advancements in the field of allergy treatment. In December 2020, MEDA Pharma GmbH & Co. KG successfully completed a trial for Treatment A (Dymista), which is a fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5. This significant milestone highlights ongoing efforts to enhance therapies for allergies and offers hope to individuals who suffer from these conditions.